CORDIS · 115618 · FP7
DRIVE-AB DRIVING RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE
Coordinator: ASTRAZENECA AB (SE)
Antimicrobial resistance (AMR) is widespread. Its global human and economic burden is tremendous and increasing annually. Yet today only a few pharmaceutical companies retain active antibacterial drug discovery programmes. While the elaboration of antibiotics with novel mechanisms of action is scientifically complex, the chief challenge is diminishing incentives. Pre-market regulatory requirements and increased control on post-market access, use, and pricing of new antibiotics are strong deterrents to drug development. Meanwhile, healthcare payers are not currently prepared to reimburse antib…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
Co-funding: the European Union contributes €6.3M toward a total project budget of €11.0M — a funding rate of 57%, with the remainder covered by the consortium partners. The project runs over approximately 3.2 years from 2014-10-01 to 2017-12-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from SE
see all →- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · FP7 · €109.4M
- GrapheneCore1 — Graphene-based disruptive technologies696656 · H2020 · €89.0M
- GrapheneCore2 — Graphene Flagship Core Project 2785219 · H2020 · €88.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · FP7 · €75.3M
- 2D-EPL — Graphene Flagship 2D Experimental Pilot Line952792 · H2020 · €20.0M
- BrightnESS — Building a research infrastructure and synergies for highest scientific impact on ESS676548 · H2020 · €19.9M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
- GSC DA — GMES Space Component Data Access223001 · FR · €48.0M
- MAAXIMUS — More Affordable Aircraft structure through eXtended, Integrated, and Mature nUmerical Sizing213371 · DE · €40.2M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the JTI-CP-IMI funding scheme.
- What is the EU contribution?
- The European Commission contributes €6.3M toward a total project budget of €11.0M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by ASTRAZENECA AB (SE).
- What is the project timeline?
- The project runs from 2014-10-01 to 2017-12-31 — approximately 3.2 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 115618.